期刊
PARKINSONISM & RELATED DISORDERS
卷 15, 期 -, 页码 S3-S8出版社
ELSEVIER SCI LTD
DOI: 10.1016/S1353-8020(09)70004-5
关键词
L-dopa; Parkinson's disease; Dopamine; Dyskinesia; Selegiline
Dopamine (DA) supplementation therapy by L-dopa for Parkinson's disease (PD) was established around 1970. The dose of L-dopa can be reduced by the combined administration of inhibitors of peripheral L-amino acid decarboxylase (AADC), catechol O-methyltransferase (COMT). or monoamine oxidase B (MAO B). DA in the striatum may be produced from exogenously administered L-dopa by various AADC-containing cells. Such us serotonin neurons. The long-term administration of L-dopa in PD patients may produce L-dopa-induced dyskinesia (LID). which may be due to chronic overstimulation of supersensitive DA D1 receptors. L-dopa may be used in combination with various new strategies Such as gene therapy or transplantation in the future. (c) 2008 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据